U.S. markets closed

Nymox Pharmaceutical Corporation (NYMX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7200+0.0300 (+1.78%)
At close: 4:00PM EDT
Show:
Balance Sheet
Cash Flow
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Breakdown
ttm
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Total Revenue
5
5
116
299
224
Cost of Revenue
4
4
58
138
149
Gross Profit
1
1
58
161
75
Operating Expense
11,721
11,721
13,383
10,802
13,310
Operating Income
-11,720
-11,720
-13,325
-10,641
-13,235
Net Non Operating Interest Income Expense
-15
-15
175
54
-193
Other Income Expense
-3
-3
-12
-7
-1
Pretax Income
-11,738
-11,738
-13,162
-10,594
-13,429
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-11,738
-11,738
-13,162
-10,594
-13,429
Diluted NI Available to Com Stockholders
-11,738
-11,738
-13,162
-10,594
-13,429
Basic EPS
-
-
-0.19
-0.18
-0.26
Diluted EPS
-
-
-0.19
-0.18
-0.26
Basic Average Shares
-
-
68,845
60,466
52,648
Diluted Average Shares
-
-
68,845
60,466
52,648
Total Operating Income as Reported
-11,720
-11,720
-13,325
-10,641
-13,235
Total Expenses
11,725
11,725
13,441
10,940
13,459
Net Income from Continuing & Discontinued Operation
-11,738
-11,738
-13,162
-10,594
-13,429
Normalized Income
-11,735
-11,735
-13,150
-10,587
-13,428
Interest Income
27
27
213
72
11
Interest Expense
42
42
18
18
52
Net Interest Income
-15
-15
175
54
-193
EBIT
-11,696
-11,696
-13,144
-10,576
-13,377
EBITDA
-11,429
-
-
-
-
Reconciled Cost of Revenue
4
4
58
138
149
Reconciled Depreciation
267
267
565
3
1
Net Income from Continuing Operation Net Minority Interest
-11,738
-11,738
-13,162
-10,594
-13,429
Total Unusual Items Excluding Goodwill
-3
-3
-12
-7
-1
Total Unusual Items
-3
-3
-12
-7
-1
Normalized EBITDA
-11,426
-11,426
-12,567
-10,566
-13,375
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0